cancer immunotherapy comes age 
activating immune system therapeutic benefit cancer long goal immunology oncology decades disappointment tide finally changed due success recent proof-of-concept clinical trials notable ability anti-ctla4 antibody ipilimumab achieve significant increase survival patients metastatic melanoma conventional therapies failed context advances understanding tolerance immunity immunosuppression regulate antitumour immune responses together advent targeted therapies successes suggest active immunotherapy represents path obtain durable long-lasting response cancer patients 
